SCWTF yields 5.70% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, SCWTF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SCWTF + JNJ for your $10,000?
Schweiter Technologies AG engages in the development, production, and distribution of extruded and cast plastic sheets, composite panels, and core materials for composite structures in Europe, the Americas, Asia, and internationally. The company offers new generation for traffic signs made from aluminum composite panels; decorative façade material and innovative roof cladding made from aluminum composite panels; individual photo wall, printed on lightweight foam sheets; and cycle shelter with optimum weather protection from extruded acrylic sheets. It also provides lightweight composite elements for buses and coaches; lightweight chassis for city buses; high-quality baths and basins from thermoformed acrylic sheets; mats and balance pads for the fitness/sports and physio market; PET rigid foams for wind farm components; structural balsa wood for wind farm components; and greenhouse made of virtually unbreakable extruded multiwall polycarbonate sheets. The company serves the display, architecture, wind energy, marine, transportation, and industrial markets. It offers its products under the AIREX, ALUCOBOND, BALTEK, DIBOND, FOREX, GATOR, KAPA, PERSPEX, SINTRA, CRYLON, and CRYLUX brands. In addition, it is involved in the property management and management activities. The company was founded in 1912 and is headquartered in Steinhausen, Switzerland.
Full SCWTF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.